A phase II, open-label, multicenter, randomized study of CDX-1401 a Dendritic Cell targeting NY-ESO-1 vaccine, in patients with malignant melanoma pre-treated with recombinant CDX-301, a recombinant human F1t3 ligand
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Fred Hutchinson Cancer Research Center
Start Date
September 1, 2013
End Date
August 31, 2014
Administered By
Duke Cancer Institute
Awarded By
Fred Hutchinson Cancer Research Center
Start Date
September 1, 2013
End Date
August 31, 2014